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Anxiety Partially Mediates Cybersickness Symptoms
in Immersive Virtual Reality Environments
Roos Pot-Kolder, MSc,1,2 Wim Veling, PhD,3 Jacqueline Counotte, MD,1 and Mark van der Gaag, PhD1,2
Abstract
The use of virtual reality (VR) in psychological treatment is expected to increase. Cybersickness (CS) is a
negative side effect of VR exposure and is associated with treatment dropout. This study aimed to investi-
gate the following: (a) if gender differences in CS can be replicated, (b) if differences in anxiety and CS
symptoms between patients and controls can be replicated, and (c) whether the relationship between exposure to
VR and CS symptoms is mediated by anxiety. A sample (N = 170) of participants with different levels of
psychosis liability was exposed to VR environments. CS and anxiety were assessed with self-report measures
before and after the VR experiment. This study replicated gender differences in CS symptoms, most of which
were present before exposure to VR. It also replicated findings that a significant correlation between anxiety and
CS can be found in healthy individuals, but not in patients. In a VR environment, anxiety partially mediated CS
symptoms, specifically nausea and disorientation. A partial explanation for the differences found between
patients and controls may lie in a ceiling effect for the symptoms of CS. A second explanation may be the
partial overlap between CS symptoms and physiological anxiety responses. CS symptoms reported at baseline
cannot be explained by exposure to VR, but are related to anxiety. Caution is required when interpreting studies
on both CS and anxiety, until the specificity in measurements has been improved. Since anxiety mediated the
CS symptoms, CS is expected to decline during treatment together with the reduction of anxiety.
Keywords: virtual reality, cybersickness, anxiety, psychosis
Introduction
The use of virtual reality (VR) in psychologicaltreatment is expected to increase now that affordable
technologies are available for clinical implementation.1 VR
can be more effective and less burdensome for patients2 and
more practical for therapists3 than in vivo (real-life) exposure
therapies. The use of VR in treating psychological disorders
was introduced about 20 years ago.4 This led to studies on VR
treatment for various anxiety disorders,5 eating and weight
disorders,6 depression,7 autism spectrum disorders,8 and
substance-related disorders,9 as well as paranoid ideation10
and hearing voices11 in psychotic disorders.
An important factor contributing to the effect of VR
treatment is immersion, that is, the sense of being present in
the virtual environment.12 However, a common drawback of
using head-mounted displays as a medium for immersive VR
environments is the experience of cybersickness (CS),13 also
known as simulator sickness. CS is the occurrence of motion
sickness-like symptoms when using VR and is related to
increased treatment dropout.1 As CS symptoms occur in 60
to 70 percent of participants,14 this has a negative impact on
treatment effects. CS is an unintended negative side effect
and efforts should be made to limit negative effects while
preserving the therapeutic effect of VR.15
Four factors are reported to influence the occurrence of
CS: (1) hardware and software choices for the VR system, (2)
design of the virtual environment, (3) task characteristics,
and (4) user characteristics.15,16 Examples of hardware and
software characteristics influencing CS are visual surround
of the display17 and navigation (e.g., a mouse, joystick or
treadmill).18 The design of the virtual environment can in-
fluence CS by using dynamic auditory stimulation19 and al-
lowed movement (active vs. passive).15 Task characteristics
known to influence CS are duration of exposure to the virtual
environment20 and training.21
User characteristics that can influence CS include gender,
affective symptoms, and mental health. Susceptibility to CS is
increased for women and varies over the menstrual cycle
due to hormonal variation; however, explanations for this
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gender difference are incomplete.22 Affective symptoms
(e.g., feeling stressed or anxious) may increase the experience
of CS23,24 but the nature of this relationship remains unclear.
VR treatment is used to expose patients to a virtual rep-
resentation of their feared stimuli. During VR treatment
patients will therefore experience high levels of anxiety.
Physiological symptoms of anxiety and CS overlap and
may confound both scientific research24 and clinical practice.
Anxiety disorders are much more prevalent in women,25
making gender-specific relationships between CS, anxiety,
and VR used in psychological treatment, an area of interest.
It is also unclear why different findings emerge in healthy
individuals and patients. For example, significant correla-
tions between levels of experienced anxiety and CS were
found in healthy controls,26 but not in patients diagnosed with
persecutory delusions exposed to a neutral VR environment.27
High levels of CS symptoms were found in patients with
an anxiety disorder even before immersion in VR.28 Corre-
lations were found between some CS symptoms and reported
anxiety in a sample with both healthy controls and patients
with an anxiety disorder.29 Some CS symptoms may reflect
anxiety more than side effects.30 Thus, more clarity is re-
quired as to which user characteristics influence CS.
The present study aimed to investigate the following: (a) if
gender differences in CS can be replicated, (b) if differences
in anxiety and CS symptoms between patients and controls
can be replicated, and (c) whether the relationship between




A total of 170 participants aged 18–35 years were earlier
recruited for a large VR study.31
From these, we defined a high liability patient group based
on phenotype, that is, the experience of (subclinical) psy-
chotic symptoms. This group consisted of two categories:
- Fifty-five patients with a psychotic disorder according to
the DSM-IV, with the exception of substance-induced
psychotic disorder, and psychotic disorder due to a
medical condition. These patients were recruited at five
outpatient departments.
- Twenty patients with an at-risk mental state (ARMS),
recruited among patients seeking help for nonpsychotic
psychiatric problems at two outpatient departments.
The low psychosis liability control group consisted of:
- Forty-two siblings of people diagnosed with a psychotic
disorder who had no personal history of a psychotic
disorder themselves.
- Fifty-three control persons recruited from the general
population; they had no history of psychotic disorder nor
a first-degree relative with a psychotic disorder.
Our previous study in this cohort found no difference in
reported symptoms between the siblings and healthy con-
trols,31 allowing to combine both groups for the analysis.
The exclusion criteria were poor command of the Dutch
language, epilepsy, and intelligence quotient (IQ) p75.
Ethical approval
This study was approved by the Medical Ethics Committee
of the Leiden University Medical Center (NL37356.058.12/
P12.182). Written informed consent was obtained from all
participants.
VR setting
The virtual environment used in this experiment was a
café. Participants could navigate the virtual environment
using a Logitech F310 Gamepad. The Sony HMZ-T1 head-
mounted display used for VR display of the café had a
high-density resolution of 1280 · 720 (per eye), with 51.6
diagonal field of view, and built-in headphones. A 3DOF
tracker (UM7 Orientation Sensor; CH-Robotics) was added to
the Sony HMZ-T1 for head rotation. The researcher controlled
the VR system and actions in the virtual environment using a
graphical user interface.
Detailed information on the conditions is already pub-
lished.31 The social stressors used in this virtual social en-
vironment (population density, ethnic density, and hostility)
were found to elicit feelings of anxiety.31 All participants
participated in five conditions, each with different levels of
social stress. Exposure to each condition lasted 4 min. The
order of the five conditions was randomized to prevent a
sequence effect.
FIG. 1. Hypothesis related to
mediation. VR, virtual reality.























































Diagnostic instruments. The Comprehensive Assessment
of At-Risk Mental States32 was used to assess ARMS before
participation. Psychotic disorder was diagnosed with either the
Comprehensive Assessment of Symptoms and History33 or the
Schedules for Clinical Assessment in Neuropsychiatry.34
Anxiety was assessed by self-rated momentary subjective
fear in units on an analog scale (subjective unit of distress
[SUD]), ranging from 0 (no distress at all) to 100 (worst
possible distress). Anxiety was first assessed before the ex-
periments. Participants also rated their maximum anxiety
during VR immediately after each of the five experiments.
The mean of these five maximum anxiety scores was cal-
culated and used for the analyses.
The self-report Simulator Sickness Questionnaire (SSQ)35
was administered before and after the VR experiments. The
SSQ measure’s three distinct symptom clusters were labeled
as Oculomotor (eyestrain, difficulty focusing, blurred vision,
headache), Disorientation (dizziness, vertigo), and Nausea
(nausea, stomach awareness, increased salivation, burping). The
SSQ was scored according to the procedures by Kennedy et al.35
Analyses
Analyses were conducted with IBM SPSS version 23. For
sociodemographic characteristics, differences in continuous
variables between the groups were analyzed using t tests. If
the distribution of a continuous variable was skewed a
Wilcoxon rank-sum test was used. Group differences in
categorical variables were tested using v2 analysis. Pearson’s
correlation coefficient (two-tailed) was used for correlations.
We used the MEMORE method36 for two-condition
within-participant statistical mediation analysis. The single
test path-analytic approach by MEMORE eliminates the
need for multiple discrete hypothesis tests about components
of the mediation model, as the previous dominant approach37
requires. A single test decreases the probability of an error
occurring. The conditions were no exposure (baseline) and
exposure to VR. MEMORE can be used to estimate the total
(c), direct (c’), and indirect (ab) effects of exposure to VR on
CS and its subscales through anxiety in a two-condition re-
peated measures design. Bootstrapping (5,000 samples) was
used. Fixed covariates such as gender (or other stable indi-
vidual differences) are accounted for in the MEMORE model.
Results
Demographics
A total of 170 participants were included: 95 controls in
the low-liability group and 75 patients in the high-liability
group. Sociodemographic characteristics of the participants
Table 1. Characteristics of the Study Sample for All Participants, for Females











(N = 75) p
Sex, female, n (%) 73 (42.9%) 47 (49.5%) 26 (34.7%) 0.053
Age, years 25.4 (4.6) 24.7 (4.4) 25.9 (4.8) 0.126 25.4 (4.6) 25.4 (4.7) 0.943
Non-Dutch origin, n (%) 58 (34.3%) 27 (37.0%) 31 (32.0%) 0.052 27 (28.7%) 31 (41.3%) 0.078
Controls, n (%) 95 (55.9%) 47 (64.4%) 48 (49.5%) 0.054
Level of education, n (%) 0.818 0.002**
No/primary 3 (1.8%) 1 (1.4%) 2 (2.1%) 0 3 (4%)
Vocational ((V)MBO) 57 (33.7%) 22 (30.6%) 35 (36.1%) 24 (25.5%) 33 (44%)
Higher secondary
(HAVO/VWO)
29 (17.2%) 12 (16.7%) 17 (17.5%) 14 (14.9%) 15 (20%)
Higher tertiary (HBO/
University)
80 (47.3%) 37 (51.4%) 43 (44.3%) 56 (59.6%) 24 (32%)
Medication use, n (%) 0.038* <0.001**
None 112 (65.9%) 54 (74%) 59 (60.8%) 88 (92.6%) 24 (32%)
Antipsychotic 35 (20.6%) 5 (6.9%) 19 (19.6%) 0 (0%) 35 (46.7%)
Antidepressant 19 (11.2%) 7 (9.6%) 7 (7.2%) 2 (2.1%) 17 (22.7%)
Benzodiazepine 10 (5.9%) 5 (6.9%) 3 (3.1%) 0 (0%) 10 (13.3%)
Other 11 (6.5%) 2 (2.7%) 9 (9.3%) 4 (4.2%) 7 (9.3%)
Anxiety before VR 21.3 (21.3) 22.2 (21.6) 20.7 (21.2) 0.627 13.8 (14.1) 30.8 (24.9) <0.001**
Anxiety during VR 32.3 (24.7) 34.4 (24.9) 30.7 (24.5) 0.252 24.0 (18.8) 42.8 (27.2) <0.001**
CS total before VR 32.7 (37.7) 42.3 (44.2) 25.6 (30.4) 0.011* 20.6 (26.8) 47.9 (43.7) <0.001**
CS total after VR 46.7 (38.7) 61.4 (41.4) 35.7 (32.6) <0.001** 44.9 (39.3) 49.0 (38.0) 0.377
Oculomotor before VR 32.7 (33.3) 42.1 (37.6) 25.6 (27.6) 0.004** 22.6 (26.7) 45.5 (36.3) <0.001**
Oculomotor after VR 33.3 (30.6) 43.7 (33.9) 25.4 (25.4) <0.001** 29.3 (29.3) 38.3 (31.6) 0.034*
Nausea before VR 23.3 (29.2) 28.0 (33.2) 19.6 (25.2) 0.121 12.3 (18.1) 37.0 (34.6) <0.001**
Nausea after VR 40.3 (36.1) 52.5 (36.8) 31.1 (32.7) <0.001** 40.6 (37.4) 39.9 (34.5) 0.955
Disorientation before VR 27.8 (46.5) 38.4 (56. 8) 19.7 (34.7) 0.008** 17.5 (34.0) 40.6 (56.1) 0.001**
Disorientation after VR 54.0 (51.9) 71.5 (58.7) 40.6 (41.7) <0.001** 54.2 (52.1) 53.6 (51.9) 0.970
Note: Values are presented as mean (standard deviation) or n (%). CS was measured by the self-report SSQ. Anxiety was assessed by
self-rated momentary subjective fear (SUD 0-100). Group differences between controls and patients of continuous variables were analyzed
using a t test, or Wilcoxon’s rank sum if skewed. Group differences of categorical variables were analyzed with v2.
*p < 0.05; **p < 0.01.
CS, cybersickness; SSQ, Simulator Sickness Questionnaire; SUD, subjective unit of distress; VR, virtual reality.






















































as well as anxiety and CS scores are presented in Table 1.
Controls had a higher level of education and a lower use of
psychiatric medication. There was a trend of more female
participants in the control group.
Gender
At baseline, 90 percent of women and 86 percent of men
reported at least one symptom of CS. Women reported more
CS symptoms than men, both overall and for each CS sub-
scale. These differences were present both before and after
exposure to VR.
No significant gender difference was found in the increase
in total CS symptoms when exposed to VR (rank sum Z = 1.19;
p = 0.24), or for oculomotor and disorientation separately.
Women reported a stronger increase in nausea than men (rank
sum Z = 2.31; p = 0.02) when exposed to VR. Results for both
overall CS and for each of the three symptom categories
separately are presented in Figure 2. No differences were
found between men and women in reported anxiety, either
before or during exposure to VR.
Patients and controls
At baseline, 81 percent of the controls and 96 percent of
the patients reported at least one symptom of CS. Patients
reported significantly more symptoms of CS at baseline than
the controls. After exposure to VR, there was no significant
difference in nausea and disorientation between the two
groups. Results for both overall CS and for each of the three
symptom categories separately are presented in Figure 3.
At baseline, there was a significant correlation between
anxiety and CS for patients (r = 0.33, p < 0.01), whereas this
was not found for the controls (r = -0.03, p = 0.74). In con-
trast, after exposure to VR, patients no longer showed a
significant correlation between anxiety and CS (r = 0.19,
p = 0.11), whereas the controls did (r = 0.53, p < 0.01).
Anxiety as mediator variable
For all 170 participants, a significant correlation was
found between anxiety and CS at baseline (r = 0.33, p < 0.01)
and after exposure to VR (r = 0.34, p < 0.01).
Mediation results are presented in Table 2.
Anxiety mediated the relationship between exposure to a
VR environment and the experience of CS. The direct effect
(c’) remained significant, implying that the mediation effect
of anxiety on CS was partial. Examination of the CS sub-
scales revealed that the relationship between exposure to VR
and nausea was partially mediated by anxiety. The rela-
tionship between exposure to VR and disorientation was also
partially mediated by anxiety. Oculomotor symptoms had no
direct relationship (c) with exposure to VR.
Discussion
In this VR study, the large majority of patients and con-
trols reported at least one symptom of CS. We replicated
both gender differences in CS and differences in CS between
patients and controls. The relationship between exposure to
VR and CS was partially mediated by anxiety. This implies
that part of the relationship between exposure to VR and CS
symptoms, more specifically nausea and disorientation, was
explained by anxiety as an intermediary variable.
Women reported more CS symptoms than men, but most of
these differences were already present at baseline. When ex-
posed to VR, women had a steeper increase in nausea symp-
toms. The gender difference in severity of CS symptoms is
FIG. 2. By gender, CS symptoms before and after exposure to VR. *p < 0.05; Women show a significantly steeper
increase in nausea symptoms when exposed to VR compared with men. CS, cybersickness.






















































in accordance with others.22 However, gender differences in
oculomotor and disorientation symptoms existed before VR
exposure and cannot be explained by either exposure to VR or
anxiety levels.
Our results replicate both findings about CS symptoms
being present before exposure to VR in patients with an
anxiety disorder,28 and associations found between anxiety
and CS symptoms.29,30 Our results replicate findings that
significant correlations between anxiety and CS were found
in controls26 but not in patients.27,28 Our study indicates that
a partial explanation may lie in a ceiling effect for CS
symptoms, that is, CS symptoms were already high in pa-
tients before VR and remained high, whereas they were
low in healthy controls before VR and increased during VR.
A second explanation may be the partial overlap between CS
symptoms and physiological anxiety responses.
CS symptoms reported at baseline cannot be explained by
exposure to VR, but are related to anxiety. The present study
found that anxiety was a mediating factor for nausea and dis-
orientation symptoms of CS, but not oculomotor symptoms.
Table 2. Effect of the Mediator Variable ‘‘Anxiety’’ on the Relationship Between Virtual
Reality Exposure and Cybersickness, Both Overall and for Each
of Its Three Subscales in All Participants (N = 170)
Effect SD P 95% CI
CS total
Total effect (c) -13.77 2.87 <0.001** -19.44 -8.08
Direct effect (c’) -9.13 3.40 0.008** -15.85 -2.41
Indirect effect (ab) -4.64 2.11 0.018a,* -9.06 -0.79
Oculomotor
Total effect (c) -0.58 2.15 0.787 -4.82 3.66
Nausea
Total effect (c) -17.10 3.01 <0.001** -23.05 -11.15
Direct effect (c’) -11.73 3.55 0.001** -18.74 -4.73
Indirect effect (ab) -5.37 2.20 0.009a,** -10.22 -1.43
Disorientation
Total effect (c) -26.26 3.83 <0.001** -33.84 -18.69
Direct effect (c’) -20.45 4.56 <0.001** -29.45 -11.44
Indirect effect (ab) -5.82 2.96 0.027a,* -12.12 -0.41
aSobel test was used to estimate p value of indirect effects. CS was measured by the self-report SSQ. Anxiety was assessed by self-rated
momentary subjective fear (SUD). MEMORE was used for two-condition within-participant statistical mediation analysis. The conditions
were no exposure (baseline) and exposure to virtual reality. Fixed covariates, such as gender, are accounted for in the MEMORE model.
*<0.05; ** <0.01.
SD, standard deviation.
FIG. 3. By group, CS symptoms before and after exposure to VR.






















































This suggests that anxiety may impact some, but not all
symptoms of CS. This is in line with studies showing five
individual symptoms of CS (general discomfort, fatigue,
headache, difficulty concentrating, and fullness of head) to
correlate with reported anxiety.29,30 Especially two CS symp-
toms, general discomfort and difficulty concentrating, may
reflect anxiety symptoms as they significantly load on the
anxiety factor.30 This is also in line with a study demonstrating
that nausea symptoms are affected by reported anxiety.24
We found no increase in oculomotor symptoms after ex-
posure to VR; previous research on the profile of CS found
that oculomotor symptoms are the least likely to occur,38
which may have influenced the statistical power. It is also
possible that oculomotor symptoms (e.g., eyestrain and blurred
vision) are physiologically less related to anxiety symptoms.
The fact that mediation by anxiety is partial and is consistent
with the finding that multiple factors influence CS.18
Strengths and limitations
The primary strength of the study is that the CS symptoms
were measured before and after exposure to VR. Also, three
different CS subscales were measured instead of only nausea,
or using a single-sickness scale. Second strength is that the
inclusion of both patients and controls allowed examining
group differences. Thirdly, the MEMORE method simulta-
neously used the CS and anxiety scores before exposure to VR,
as well as scores after exposure, to estimate mediation effects.
On the contrary, the statistical power of this study was
limited, as many participants reported little CS and little or
no anxiety symptoms; this impeded more detailed analysis of
the subgroups. Four of the SSQ items load on two subscales
instead of one, which inflate the contribution of these items
on the total score. As two of these items, general discomfort
and difficulty concentrating, are known to be correlated with
anxiety,30 this might have affected analysis.
Only two specific patient groups were included and all
participants were relatively young; both these factors limit
the generalizability of our findings. Also, this study exam-
ined state anxiety only, whereas additional affect states
should be explored in future research. As a stable individual
difference trait, anxiety is accounted for in the MEMORE
model. However, as it can influence both the anxiety re-
sponse and the CS symptoms, more research is required to
clarify its potential role. Another limitation is that anxiety
was measured with self-report. Finally, this study used the
diagnostic criteria of the DSM-IV instead of the current
DSM-V; however, as there are only marginal differences in
the categories of psychotic disorders39 the effect on the in-
dividual diagnosis of each patient in the present study can be
considered negligible.
Clinical implications and future directions
This study indicates that caution is required when inter-
preting studies on both CS and anxiety, until the specificity in
measurements has been improved. Gender differences in CS
should also be taken into account. Findings on CS based on
controls cannot be generalized to patients. Reported anxiety
symptoms may partially reflect CS symptoms and vice versa.
The relationship between VR exposure and CS symptoms is
partially explained by anxiety as an intermediary variable.
When VR therapy reduces anxiety, the nausea and disori-
entation symptoms are expected to decline. In addition, CS
symptoms decrease after repetitive use of VR.40 If a patient
reports anxiety and CS during the first stages of VR treat-
ment and can tolerate this, we recommend to continue with
VR treatment.
Future research should include patients diagnosed with an
anxiety disorder, and measure both state and trait anxiety.
Replication with a larger sample size of a broad age range is
necessary to be able to perform more detailed analysis of
subgroups and further clarify mechanisms.
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